Exploring the Impact of MRD in CLL Treatment

The chapter delves into the considerations surrounding the use of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukemia (CLL) treatment, discussing the challenges, tools like flow cytometry and NGS, and tailoring testing based on treatment types. It emphasizes the significance of MRD in treatment decisions, citing a UK study focusing on MRD-guided treatments to achieve undetectable MRD levels and deeper disease eradication.